These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34663374)

  • 1. Examining prevalence and correlates of smoking opioids in British Columbia: opioids are more often smoked than injected.
    Parent S; Papamihali K; Graham B; Buxton JA
    Subst Abuse Treat Prev Policy; 2021 Oct; 16(1):79. PubMed ID: 34663374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
    Kamal A; Ferguson M; Xavier JC; Liu L; Graham B; Lock K; Buxton JA
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):27. PubMed ID: 37194018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: A cross-sectional analysis.
    Moustaqim-Barrette A; Papamihali K; Crabtree A; Graham B; Karamouzian M; Buxton JA
    Drug Alcohol Depend; 2019 Dec; 205():107609. PubMed ID: 31654839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada.
    Papamihali K; Yoon M; Graham B; Karamouzian M; Slaunwhite AK; Tsang V; Young S; Buxton JA
    Harm Reduct J; 2020 Nov; 17(1):90. PubMed ID: 33228676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
    Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
    PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A qualitative study on perceptions and experiences of overdose among people who smoke drugs in Vancouver, British Columbia.
    Ivsins A; Bonn M; McNeil R; Boyd J; Kerr T
    Drug Alcohol Depend; 2024 May; 258():111275. PubMed ID: 38581922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologic oxygen responses to smoking opioids: an observational study using continuous pulse oximetry at overdose prevention services in British Columbia, Canada.
    Moe J; Buxton JA; Wang YE; Chavez T; Feldman-Kiss D; Marr C; Purssell RA; Otterstatter M
    Harm Reduct J; 2024 May; 21(1):89. PubMed ID: 38702702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study.
    Gomes T; Khuu W; Craiovan D; Martins D; Hunt J; Lee K; Tadrous M; Mamdani MM; Paterson JM; Juurlink DN
    Drug Alcohol Depend; 2018 Oct; 191():86-90. PubMed ID: 30096638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motivators of and barriers to drug checking engagement in British Columbia, Canada: Findings from a cross-sectional study.
    Tobias S; Ferguson M; Palis H; Burmeister C; McDougall J; Liu L; Graham B; Ti L; Buxton JA
    Int J Drug Policy; 2024 Jan; 123():104290. PubMed ID: 38101275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study.
    Corser J; Palis H; Fleury M; Lamb J; Lock K; McDougall J; Mehta A; Newman C; Spence H; Buxton JA
    Harm Reduct J; 2022 May; 19(1):46. PubMed ID: 35590375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.
    Selfridge M; Card K; Kandler T; Flanagan E; Lerhe E; Heaslip A; Nguyen A; Moher M; Pauly B; Urbanoski K; Fraser C
    Int J Drug Policy; 2022 Jul; 105():103709. PubMed ID: 35525052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
    Smolina K; Crabtree A; Chong M; Park M; Mill C; Zhao B; Schütz CG
    Subst Abus; 2022; 43(1):92-98. PubMed ID: 32441588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.